Sinopharm Raises $716 Million In Secondary Offering
Sinopharm Group (HK: 1099), China's largest drug distribution company, raised $716 million through a secondary issue to a "handful" of institutional investors, who purchased 199 million new shares (see story). The issue increases Sinopharm's outstanding shares by 7.74%. The company said the new capital will help Sinopharm expand its network (it did not specify whether the growth would come from internal growth or through M&A) and to replenish liquidity after its already completed growth initiatives.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.